DarioHealth (NASDAQ:DRIO) Announces Quarterly Earnings Results

DarioHealth (NASDAQ:DRIO – Get Free Report) released its earnings results on Thursday. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.22, Zacks reports. The firm had revenue of $5.31 million during the quarter, compared to analysts’ expectations of $5.21 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%.

Here are the key takeaways from DarioHealth’s conference call:

  • Revenue rose 6% year over year to $5.3 million, while direct-to-consumer revenue grew about 48% and increased to 53% of total revenue. The company still posted an $8.8 million net loss.
  • Contracted and late-stage ARR was approximately $13.1 million, with management expecting a gradual conversion into revenue through 2027 and 2028; about 40% is tied to health-plan ASO agreements, which can take longer to activate. Management said it remains on a path to break-even in 2028.
  • Channel partners generated about 75% of new accounts, including a third state health-plan win through Amwell, covering roughly 1.5 million lives. However, the New Jersey ASO opportunity is not expected to contribute significantly until the second half of 2027.
  • Operating expenses fell 10% year over year to $11.2 million, and operating loss narrowed 15% to $8.0 million. Dario ended the quarter with $31.2 million in cash and short-term deposits, following a July registered direct offering.
  • Management said DarioIQ’s engagement results support up to an approximately 14% increase in engagement-based ARR at existing customers, and cited AI as one contributor to lower operating costs. The company is also pursuing GLP-1, women’s health, and sleep offerings, though their revenue contribution and rollout pace remain uncertain.

DarioHealth Price Performance

DarioHealth stock opened at $1.65 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. DarioHealth has a 1 year low of $1.45 and a 1 year high of $14.77. The firm’s 50-day moving average is $5.15 and its 200-day moving average is $7.37.

Analyst Ratings Changes

Several research firms have commented on DRIO. Weiss Ratings restated a “sell (e+)” rating on shares of DarioHealth in a report on Tuesday, October 6th. BTIG Research started coverage on DarioHealth in a research note on Tuesday, October 27th. They set a “buy” rating and a $6.00 price objective on the stock. Alliance Global Partners began coverage on shares of DarioHealth in a research note on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price for the company. Finally, TD Cowen lowered their price target on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Get Our Latest Stock Analysis on DRIO

DarioHealth Company Profile

(Get Free Report)

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health. The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.

Further Reading

Earnings History for DarioHealth (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.